Vilon

Vilon information

CAS No.: 45234-02-4
Peptide Sequence: H-Lys-Glu-OH
Molecular Formula: C11H21N3O5
Molecular Weight: 275.3
Appearance: White Lyophilized powder

What is Vilon?

At just two amino acids in length, Vilon is the shortest peptide known to have biological activity. Research shows that Vilon has potent anti-aging effects and that it is a powerful regulator of immune function.There is also good evidence that Vilon helps to regulate the vascular system and promotes hemostasis. Vilon has been shown to reduce the incidence and growth of spontaneous tumors, though its role as an adjuvant in cancer treatment (as opposed to prevention)has been called into question. Overall, Vilon has several staunch advocates,such as Dr.Vladimir Anisimov, who feel that the peptide is a useful geroprotective agent.x

What does Vilon work for?

Vilon and Aging

Research in mice shows that subcutaneous administation of Vilon increases physical activity and endurance while helping to reduce the risk of cancer. These two effects resulted in longer lifespan in the treated mice,suggesting that Vilon may be a legitimate anti-aging peptide.This is especially encouraging given that it produced no adverse effects in the mice following long-term administration.

Interestingly, the research shows that the earlier Vilon is administered, the greater its effects seem to be. In other words,giving Vilon to young mice enhances lifespan more than if Vilon is not administered until the mice are much older. This same effect was seen in early studies looking at crude thymic and pineal extracts given to mice to slow down aging[8]. The speculation is that Vilon and similar peptides,when administered late in life, can reverse senescence in existing cells but can obviously do nothing for cells that have already been eliminated through apoptosis. By administering Vilon 20mg early in life, cells get the greatest amount of protection and so turnover is slowed down. The result is that more cells stay healthy for longer periods of time,slowing the need to replace them and preserving limited stem cell lines.

Vilon’s anti-aging effects seem to extend to Gl function as well,where the peptide has been shown to improve the activity of certain enzymes in the Gi tracts of older mice. The peptide also appears to improve barrier function, thus reducing the incidence of leaky gut, enhancing disease resistance,and improving the overall health of the Gl tract in older mice[9]. Research shows that Vilon thereby helps to improve glucose and glycine absorption in the small intestine of older rats[10]. These features of Vilon may help to maintain nutrient extraction with age,thereby improving overall well-being and perhaps enhancing longevity.

Dr.Vladimir N.Anisimov,who has been researching aging and cancer development since the 1970s, points out that the thymus is one of two glands (the other being the pineal gland) that plays an important role in regulating aging. The healthier the thymus is, the healthier we are as individuals. Of course, Vilon is a thymic peptide and affects cells, like lymphocytes,that are produced in and mature in the thymus. Dr. Anisimov is a staunch advocate for using peptide bioregulators in the prevention of cancer[11]. He is a close colleague of Dr.Vladimir Khavinson.

The history of Vilon

Irregular skin pigmentation can be a significant cause of signs of aging and a person’s lack of mental health. Despite the large number of skin lightening agents available, there is still an opportunity to identify more effective agents, ie agents that target alternative biological mechanisms. OBJECTIVE: To provide clinical evidence of the skin lightening effect of the tetrapeptide Pro-Lys-Glu-Lys (PKEK) in V-VI skin subjects living in South Africa. Pro-Lys-Glu-Lys was evaluated in a double-blind and vehicle-controlled clinical study using expert grading of digital images by comparing its effects on skin with facial melasma and post-inflammatory hyperpigmentation Effects of Types V-VI Subjects. This study demonstrates the efficacy of PKEK in subjects with skin types V-VI. When comparing the two treatments, the formulation containing the skin lightening peptide was significantly better than the vehicle in overall appearance (P < 0.05) and skin tone evenness (P < 0.01) at 12 weeks. Tetrapeptide PKEK has demonstrated lightening effects on skin discoloration and post-inflammatory hyperpigmentation caused by melasma. These studies were performed on subjects with skin type V-VI living in South Africa, but we believe this technique is applicable to all ethnic groups.

Vilon Test reports